Stock Track | RemeGen Soars 5.07% Intraday Following NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288

Stock Track10:45

RemeGen's stock price surged 5.07% during intraday trading on Thursday, reflecting significant investor optimism.

The sharp increase appears to be a direct response to the company's announcement that it has secured approval from China's National Medical Products Administration (NMPA) to initiate a Phase I/IIa clinical study for its novel bispecific antibody-drug conjugate (ADC), RC288. The candidate is designed to treat locally advanced unresectable or metastatic malignant solid tumours.

RC288 is engineered to target two proteins, PSMA and B7H3, which are highly expressed in various solid tumours. This regulatory milestone represents a key step forward in the company's drug development pipeline, though management has noted that the trial approval is not expected to have a material impact on near-term financial performance and highlighted the inherent uncertainties of early-stage development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162762719?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 10:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162762719","market":"nz","top_or_hot":-1,"title":"Stock Track | RemeGen Soars 5.07% Intraday Following NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288","media":"Stock Track","content":"<p>RemeGen's stock price surged 5.07% during intraday trading on Thursday, reflecting significant investor optimism.</p><p>The sharp increase appears to be a direct response to the company's announcement that it has secured approval from China's National Medical Products Administration (NMPA) to initiate a Phase I/IIa clinical study for its novel bispecific antibody-drug conjugate (ADC), RC288. The candidate is designed to treat locally advanced unresectable or metastatic malignant solid tumours.</p><p>RC288 is engineered to target two proteins, PSMA and B7H3, which are highly expressed in various solid tumours. This regulatory milestone represents a key step forward in the company's drug development pipeline, though management has noted that the trial approval is not expected to have a material impact on near-term financial performance and highlighted the inherent uncertainties of early-stage development.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | RemeGen Soars 5.07% Intraday Following NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | RemeGen Soars 5.07% Intraday Following NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-02 10:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RemeGen's stock price surged 5.07% during intraday trading on Thursday, reflecting significant investor optimism.</p><p>The sharp increase appears to be a direct response to the company's announcement that it has secured approval from China's National Medical Products Administration (NMPA) to initiate a Phase I/IIa clinical study for its novel bispecific antibody-drug conjugate (ADC), RC288. The candidate is designed to treat locally advanced unresectable or metastatic malignant solid tumours.</p><p>RC288 is engineered to target two proteins, PSMA and B7H3, which are highly expressed in various solid tumours. This regulatory milestone represents a key step forward in the company's drug development pipeline, though management has noted that the trial approval is not expected to have a material impact on near-term financial performance and highlighted the inherent uncertainties of early-stage development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1162762719","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162762719","pubTimestamp":1775097929,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"RemeGen's stock price surged 5.07% during intraday trading on Thursday, reflecting significant investor optimism.The sharp increase appears to be a direct response to the company's announcement that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|RemeGen盘中大涨5.07%获NMPA批准双特异性ADC RC288 I/IIa期试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"RemeGen's stock price surged 5.07% during intraday trading on Thursday, reflecting significant investor optimism.The sharp increase appears to be a direct response to the company's announcement that it has secured approval from China's National Medical Products Administration (NMPA) to initiate a Phase I/IIa clinical study for its novel bispecific antibody-drug conjugate (ADC), RC288. The candidate is designed to treat locally advanced unresectable or metastatic malignant solid tumours.RC288 is engineered to target two proteins, PSMA and B7H3, which are highly expressed in various solid tumours. This regulatory milestone represents a key step forward in the company's drug development pipeline, though management has noted that the trial approval is not expected to have a material impact on near-term financial performance and highlighted the inherent uncertainties of early-stage development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162762719","isCrawlerRequest":true}